13. Bristol-Myers Squibb - Top 15 R&D Budgets

Who: Bristol-Myers Squibb

Based: United States

2006 Pipeline Budget: $3.39 billion €2.32

Pipeline news: After weathering several tough years, BMS seems to be on the mend. The company has spent the last few years investing heavily in its pipeline and has a lot to show for it. BMS is expected to seek approval soon for the melanoma drug ipilimumab, which is being developed in partnership with Medarex. Additionally, earlier this year BMS inked a $1 billion deal with Pfizer for apixaban, a blood clot therapy that has demonstrated promising efficacy and could go on to become a successor for Coumadin. It hasn't been all good news for BMS, however. The company's executives recently announced that they would probably not seek FDA approval of their bladder drug vinflunine, which had been a key part of BMS's strategy for a comeback in cancer therapies. Another recent announcement? The company is making major cuts to its workforce--exact numbers haven't been revealed.

Phase III drugs:
> Ixabepilone - Breast cancer, Metastic breast cancer
> Vinflunine - Gastric cancer, Transitional Cell Carcinoma of the Urothelial Tract, Bladder Cancer, Bladder Neoplasms, Transitional Cell Carcinoma, Metastasis
> Ipilimumab - Melanoma
> Belatacept - Renal Transplant, Kidney Transplantation, Chronic Kidney Failure
> Saxagliptin - Type 2 Diabetes Mellitus, Type 2 Diabetes
> Apixaban - Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Atrial Flutter, Venous Thrombosis, Pulmonary Embolism

Full Pipeline Site: Link

13. Bristol-Myers Squibb - Top 15 R&D Budgets
Read more on

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.